Iloprost Power 15 in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Patients with symptomatic idiopathic pulmonary arterial hypertension (IPAH), or familial
pulmonary arterial hypertension (FPAH) or pulmonary hypertension associated with Human
immunodeficiency virus (HIV) or drugs/toxins in New York Heart Association (NYHA) functional
class II to IV at baseline, naive to PAH treatment or currently being treated with a stable
dose of either bosentan, ambrisentan or sildenafil will be enrolled in the PROWESS 15 study.
This randomized, double blind, placebo-controlled, crossover, and single-dose study will
determine whether a single inhaled dose of iloprost using the power 15 disc improves exercise
capacity compared to placebo in patients with pulmonary arterial hypertension (PAH).